Treating adolescent depression is one of the most significant challenges in mental health, a landscape complicated by the FDA's black box warning about antidepressant-associated suicide risk. This episode dives deep into the landmark Treatment for Adolescents With Depression Study (TADS), the large-scale, NIMH-funded trial designed to bring clarity to this complex issue. We explore the study's crucial findings, from the "horse race" between fluoxetine, CBT, and their combination, to the critical data on safety and suicidality. Join us as we unpack why combination therapy emerged as a superior strategy, how CBT acts as a protective shield, and what these results mean for clinicians, families, and teens making real-world treatment decisions today.

Reference: The TADS Team. (2007). The Treatment for Adolescents With Depression Study (TADS): Long-term Effectiveness and Safety Outcomes. Archives of General Psychiatry, 64(10), 1132–1144.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit upathak.substack.com